Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 17/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 17/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 16/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 9/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992208 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL23992207 | 0.91 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL30227089 | 0.91 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL30227167 | 0.89 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL23992185 | 0.89 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL24086663 | 0.87 | HDAC1 (0.82) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL30227367 | 0.87 | HDAC1 (0.82) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL30227189 | 0.82 | HDAC3 (0.81) | HDAC3HDAC1HDAC2NCOR2HDAC10 | |
| SCHEMBL24086683 | 0.82 | HDAC3 (0.81) | HDAC3HDAC1HDAC2NCOR2HDAC10 | |
| SCHEMBL23992176 | 0.81 | HDAC3 (0.83) | HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142733-B1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS CORP (TW) | 2025-10-01 | — | — | EP | disclosed |
| US-12213971-B2 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-02-04 | — | — | US | disclosed |
| US-20230263790-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-08-24 | — | — | US | disclosed |
| US-11672788-B2 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-06-13 | — | — | US | disclosed |
| CN-116033904-A | Histone deacetylase inhibitor for tumor microenvironment immunomodulation | 华上生技医药股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4142733-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672788-B2 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | HDAC1, HDAC2, HDAC9 | HDAC3 5/4885HDAC1 1/4885HDAC2 2/4885 |
| US-20230263790-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | HDAC1, HDAC2, HDAC9 | HDAC3 5/4885HDAC1 1/4885HDAC2 2/4885 |
| US-12213971-B2 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | HDAC1, HDAC2, HDAC9 | HDAC3 5/4885HDAC1 1/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.